. Author manuscript; available in PMC: 2015 Dec 17.

Published in final edited form as: Obstet Gynecol. 2014 May;123(5):929–937. doi: 10.1097/AOG.0000000000000124

Table 3.

Baseline Cost-Effectiveness Results^*

Strategy	Total Cost (Millions)	Incremental Cost (Millions)	Total QALY (Life-Years)	Incremental QALY	Incremental Cost- Effectiveness Ratio
No intervention	246.1	−301.8	187,750,960	−42,240	7,146.0
Infant vaccination only	504.9	−43.0	187,786,320	−6,880	6,250.0
Sequential HBeAg testing	544.6	−3.3	187,796,280	3,080	Cost-saving
Current recommendation	547.9		187,793,200		Reference
Sequential HBV load testing 10⁸ copies/mL or greater as cutoff	551.2	3.3	187,795,280	2,080	1,582.7
Sequential HBV load testing 10⁶ copies/mL or greater as cutoff	555.9	8.0	187,796,640	3,440	2,339.2

QALY, quality-adjusted life years; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus.

A negative incremental cost means less cost; a negative incremental QALY saved means fewer QALYs gained.

Based on a hypothetical 2010 birth cohort of 4 million neonates and 2010 U.S. dollars, both costs and QALYs were discounted at a 3% annual rate. A negative incremental cost means less cost; a negative incremental QALY saved means fewer QALYs gained.